Drug Discovery World

APRIL 8, 2024

Class B GPCRs are recognised as important targets for new medicines, particularly in chronic endocrine and metabolic diseases. grant supports drug discovery in metabolic diseases appeared first on Drug Discovery World (DDW). Diana Spencer, Senior Digital Content Editor, DDW The post €1.6m

Disease 130

Disease Small Molecule Drugs Treatment 130

Drug Discovery World

DECEMBER 7, 2023

Inipharm has initiated Phase I dosing of its lead candidate, INI-822, which is a small-molecule inhibitor for HSD17B13, a gene implicated in nonalcoholic steatohepatitis (NASH). Loss-of-function variants of HSD17B13 are known to be associated with reduced incidence risk and severity of multiple liver diseases.

Disease 148

Disease Small Molecule Drugs Treatment 148

Drug Discovery World

MARCH 15, 2024

Biotechnology company Allyx Therapeutics has reported positive Phase Ib clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases. The findings were presented at the AD/PD 2024 Conference in Lisbon.

Disease 130

Disease Trials Small Molecule Pharmacokinetics 130

Drug Discovery World

FEBRUARY 13, 2024

AM1476 is a selective peripheral-acting 5-HT2B receptor small molecule antagonist that can be delivered orally. Systemic sclerosis is a chronic, progressive, autoimmune disease characterised by inflammation and fibrosis, such as uncontrolled scar tissue formation, in skin and various internal organs.

Disease 130

Disease Treatment Small Molecule Pharmacokinetics 130

Drug Discovery World

OCTOBER 4, 2022

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . With its recent award of $3.35 Overcoming sector challenges .

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Drug Discovery World

JANUARY 12, 2023

Through the collaboration, X-Chem will screen its DNA-encoded libraries (DEL) against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease. . “We

Disease 130

Disease Screening Hits Research Small Molecule 130

Metabolite Tales Blog

JANUARY 26, 2023

Metabolism of 2022 FDA approved small molecule drugs – Part 1 Does CYP3A4 still rule? By Julia Shanu-Wilson It won’t come as much surprise to learn that of the 17 small molecules* approved by the FDA in 2022, CYP3A4 was the major player in drug metabolism. References Iversen et al., Curr Drug Metab. 20(4): 254-265.

Small Molecule 52

Small Molecule FDA Approval FDA Drugs 52

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . The agreement encompasses Lead Pharma’s entire pipeline.

Small Molecule 52

Small Molecule Disease Immune Response Licensing 52

Drug Discovery World

AUGUST 28, 2024

JT: We are developing novel small molecule, disease-modifying, allosteric regulators to treat serious diseases such as Parkinson’s disease and other dementias. Gain’s lead drug candidate GT-02287 is a best-in-class small molecule for the treatment of GBA-Parkinson’s disease and other neurodegenerative diseases.

Research 163

Research Small Molecule Disease Therapies 163

Drug Discovery World

JULY 27, 2022

Biotechnology company Recursion has been granted an Orphan Drug Designation for its potential treatment of the rare disease familial adenomatous polyposis (FAP). . As it stands there are no approved therapies for the disease. .

Disease 130

Disease Small Molecule Clinical Trials Therapies 130

Drug Discovery World

NOVEMBER 9, 2022

The next stage will involve the identification of small molecule inhibitors to treat RSV infections. The final stage of the research plan will utilise OneThree’s AI platform to identify the drugs that are most likely to be efficacious against the identified disease targets with clean safety profiles in RSV patients. .

Disease 130

Disease Small Molecule Virus Trials 130

Drug Discovery World

NOVEMBER 11, 2022

BioSenic’s arsenic trioxide (ATO) autoimmune disease platform has completed a successful Phase IIb trial in chronic Graft vs Host Disease (cGVHD) and is preparing to move to a Phase III trial. . The properties of ATO as a small molecule are now well established,” said Prof François Rieger, President and CEO of BioSenic. .

Disease 130

Disease Small Molecule Medical Schools Trials 130

Drug Target Review

OCTOBER 11, 2023

Almost every one of us will know someone with a neurodegenerative disease such as Alzheimer’s or Parkinson’s. It is less common to know someone with a rare genetic disease; but while individually rare, collectively they have an enormous impact. This will, in turn, slow the progression of, or even halt, the disease.

Disease 113

Disease Treatment Small Molecule Therapies 113

Drug Discovery World

SEPTEMBER 5, 2024

SBL01 is a first-in-class small molecule ‘dual inhibitor of both necroptosis and ferroptosis’ Regulated cell death, such as necroptosis and ferroptosis, are key processes in acute liver failure where cells degenerate abruptly. The committee considered that this constitutes a clinically relevant advantage.”

Small Molecule 148

Small Molecule Drugs Production Regulations 148

Drug Target Review

JUNE 15, 2023

In this article Drug Target Review’s Izzy Wood spoke to Sam Hasson, Director of Target Biology at Rgenta Therapeutics, a biotech firm in Massachusetts, US, that aims to develop small molecule therapeutics to target RNA processing.

RNA 96

RNA Small Molecule Disease Assay Development 96

Drug Discovery World

JULY 19, 2024

TPD is a rapidly emerging field in drug development, exploiting a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies.

Targeted Protein Degradation 130

Targeted Protein Degradation Small Molecule Research Government 130

The Pharma Data

JULY 28, 2021

Novel small molecule drug candidates will target GPR75 to potentially address obesity and related co-morbidities. AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities.

Small Molecule 52

Small Molecule Research Science Disease 52

Drug Discovery World

NOVEMBER 8, 2023

Over 19 million 1 hearts succumb to cardiovascular disease yearly, while around 10 million 2 lives are claimed by cancer every year. By prioritising treatments for diseases with high mortality rates a standardised approval process can be established. This was the challenge embraced by researchers at John Hopkins University.

Clinical Trials 183

Clinical Trials Trials Disease Medical Schools 183

Drug Discovery World

SEPTEMBER 4, 2024

EVO756 is a highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2) and could offer the potential for once-daily oral administration without the side effects observed with other therapies.

Clinical Trials 130

Clinical Trials Trials Small Molecule Clinical Development 130

Dark Matter Blog

AUGUST 27, 2020

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. The efficiency of exon 7 inclusion in the mature SMN2 mRNA varies significantly among patients and poor inclusion efficiency correlates with higher disease severity.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

Drug Discovery World

DECEMBER 12, 2023

Exonate has now regained full rights to its complete portfolio of ophthalmology assets from Janssen Pharmaceuticals EXN407 is reportedly well placed to be the first topical treatment for retinal vascular diseases, including diabetic retinopathy and diabetic macular oedema. EXN407 is a small molecule inhibitor of splice factor kinase SRPK1.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

Drug Discovery World

JUNE 26, 2024

Spinogenix has initiated a Phase II trial to evaluate SPG302 for the treatment of adult participants with mild-to-moderate Alzheimer’s disease (AD), following approval for the trail in Australia. SPG302 is a once-a-day pill being developed as a regenerative treatment for neurodegenerative and neuropsychiatric diseases.

Small Molecule 190

Small Molecule Pharmacokinetics Clinical Trials Drugs 190

Drug Target Review

JULY 13, 2023

In this article, we will delve into the world of condensate biology and explore the groundbreaking research projects undertaken to discover the potential they hold for diseases such as amyotrophic lateral sclerosis ( ALS ) and colorectal cancer. Klein notes the importance of Dewpoint’s disease-agnostic approach.

Disease 98

Disease Small Molecule Cell Biology Medical Schools 98

Drug Discovery World

JANUARY 11, 2024

VRG50635 is a small molecule PIKfyve inhibitor and is reportedly one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform. ” The post AI-discovered ALS drug trial uses unique remote monitoring appeared first on Drug Discovery World (DDW).

Drug Trials 246

Drug Trials Trials Small Molecule Clinical Trials 246

Collaborative Drug

AUGUST 29, 2023

a new Italian incubator dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases, announced today that it has adopted Collaborative Drug Discovery’s CDD Vault as its platform of choice for managing drug discovery data.

Small Molecule 81

Small Molecule Treatment Disease Research 81

Drug Discovery World

MAY 30, 2024

A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. We are now advancing our next generation small molecules for the treatment of obesity to IND preparatory studies in H1 next year and expect to enter the clinic in 2026.”

Small Molecule 148

Small Molecule Treatment International Production 148

Drug Discovery World

MARCH 12, 2024

MJ : From the first known reference to medicinal use of plants on a Mesoptamian clay tablet written during the third millennium BC to the FDA approval of the blockbuster anticancer drug Taxol in the 1990s, natural products from plants have been at the forefront of efforts to overcome human diseases, such as cancers, hypertension, and pain.

Small Molecule 148

Small Molecule Synthetic Chemistry Production Molecular Biology 148

Drug Discovery World

AUGUST 4, 2022

Biopharmaceutical group Sosei will work together with AbbVie on a drug discovery project to discover, develop and commercialise small molecules that target neurological diseases. . Sosei will put forward its Heptares’?

Structure Based Drug Design (SBDD) 130

Structure Based Drug Design (SBDD) Small Molecule Drugs Licensing 130

Drug Discovery World

AUGUST 21, 2023

When they go awry, they often drive cancer and other disease processes like diabetes, inflammatory diseases, and neurological conditions. “At This funding will enable us to accelerate and optimise new molecules to address diseases that are driven by regulatory protein dysfunction,” said Talus Bio CEO and Co-Founder Alex Federation.

Small Molecule 245

Small Molecule DNA Drugs Licensing 245

BioPharma Drive: Drug Pricing

APRIL 22, 2024

billion, is the latest research collaboration involving small molecule drugs that modify RNA. The deal, which could be worth up to $1.8

RNA 67

RNA Small Molecule Disease Research 67

DrugBank

JULY 24, 2024

This is a game-changer, especially in the fight against cancer and other complex diseases. These multifunctional small molecules are like tiny spies, hijacking the body’s natural protein degradation system to remove unwanted proteins. This can potentially correct the root causes of some diseases at the genetic level.

Small Molecule 84

Small Molecule Clinical Trials Drugs Therapies 84

Drug Discovery World

MARCH 15, 2024

Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease.

Small Molecule 130

Small Molecule Clinical Trials Drugs Trials 130

Drug Discovery World

JULY 19, 2024

This means that we rely on non-human, animal models to test drugs that can have effects on blood cell production and in targeting blood diseases (such as leukaemias). However, they are challenging to culture in the lab as they quickly change or die once out of the body.

Small Molecule 130

Small Molecule Drugs Engineering Disease 130

Drug Discovery World

MAY 31, 2024

Dual receptor beta-agonist promotes healthy weight loss A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. The post This week in drug discovery (27-31 May) appeared first on Drug Discovery World (DDW).

Small Molecule 130

Small Molecule Clinical Trials Drugs Trials 130

Drug Discovery World

FEBRUARY 12, 2024

By inhibiting myofibroblasts’ deposition of extracellular matrix, the candidate demonstrates substantial potential in mitigating fibrotic diseases. Anima Biotech has identified a preclinical candidate, effectively disrupting the transformation of fibroblasts into fully differentiated myofibroblasts.

Small Molecule 130

Small Molecule Disease Therapies Production 130

DrugBank

MAY 15, 2024

Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. Among these targets are proteins, receptors, and enzymes that are fundamental to disease mechanisms.

Small Molecule 83

Small Molecule Molecular Biology Drugs Disease 83

Drug Discovery World

APRIL 24, 2024

Evotec and Variant Bio have announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. Despite the chronic nature of fibrotic conditions, widespread impact on various organs, and substantial disease burden, there is currently no curative treatment for these conditions.

Treatment 130

Treatment Small Molecule Clinical Development Disease 130